The primary endpoint is normally objective response. The study will seek to enroll approximately 30 patients.. Allos Therapeutics reports net lack of $20.5 million for first-quarter 2010 Allos Therapeutics, Inc. today reported economic results for the 1st quarter ended March 31, 2010.S. Non-GAAP gross product sales, or sales to pharmaceutical low cost distributors, were $8.7 million for the first quarter of 2010. Allos markets FOLOTYN to distributors who after that resell FOLOTYN to sufferers’ health care providers. GAAP gross revenue, or sell-through product sales from distributors to healthcare providers, were $8.2 million for the first quarter of 2010. Provided the limited sales history for FOLOTYN, Allos currently cannot reliably estimate expected returns at the right period of shipment to it is distributors.Professor Hartmut Ehrlich, M.D., CEO of ABIVAX, said: We are confident that ABX203, our therapeutic vaccine against chronic hepatitis B could be a major improvement in the treating patients with this devastating disease. This pivotal Phase IIb-III study that people have announced today is made to concur that ABX203 can deliver meaningful clinical benefits with regards to long-term viral control, today with the current standard of care an objective that cannot be achieved. Gerardo Guillen, PhD, mind of R&D at CIGB in Havana, commented: This first-in course therapeutic vaccine is awaiting market authorization in Cuba and we have become pleased to see the great progress our partner Abivax is normally making with the worldwide development of this world leading immunotherapeutic to take care of chronic hepatitis B.